Vigilent Labs to distribute COVID-19 test kits and digital health credentials see more
Enables Vigilent Labs to distribute COVID-19 test kits and digital health credentials to government organizations through GSA schedule
Vigilent Labs, an advanced health and medical technology company that provides solutions for the detection, identification and assessment of health and bio-threats, has formed a partnership with Seroclinix and Davenport Aviation to distribute COVID-19 test kits and Vigilent Labs v.Pass digital credential technology through Davenport Aviation’s General Services Administration (GSA) Contract.
“Our government division has worked on adding much-needed medical supplies to our GSA contract to meet our nation’s most pressing needs during the COVID-19 pandemic,” said Rob McMillin, Davenport’s Senior Program Manager. “We are pleased to partner with Vigilent Labs and Seroclinix to provide test kits to government customers through our GSA Contract (#GS-07F-139DA).”
The COVID-19 Rapid Test kit partnership with SeroClinix’s cost-effective SIENNA Antibody Tests produces fast, reliable and accurate results in seven to 10 minutes, which are CE-marked useful for COVID-19 screening and surveillance under CDC guidance, recently received high marks fro3m the latest International Journal of Infectious Diseases evaluation, and now authorized and approved for purchase through GSA Advantage. A critical advantage of this partnership is the Vigilent Labs “v.LABS” platform and its ability to convert the SIENNA test results into a digital credential that includes one’s COVID-19 Test Results in a v.PASS, facilitating near-real-time health surveillance.
“Vigilent Labs leverages our existing capability with leading-edge technology to provide a comprehensive solution to the medical community from the Point Of Care environment to the executives and managers responsible for healthcare decision making,” said John Falk, President of Vigilent Labs. “We are proud of this strategic partnership and to provide quality testing and credential solutions to government organizations.”
This partnership marks an important milestone for Vigilent Labs as an authorized GSA/Government reseller and distributor for COVID-19 Antigen and Antibody test kits in the United States for the United States government.
“We are excited for our partnership with Vigilent Labs in providing fast and effective test kits for the government,” said Howard Lee, Chief Executive Officer of Seroclinix. “These tests are not only cost-effective but also have the highest reviews made by independent medical evaluations as to the accuracy of the test.”
To learn more about Vigilent Labs’ solutions for COVID-19 testing and monitoring, visit www.vigilentlabs.com.
About Vigilent Labs
Vigilent Labs is an advanced health and medical technology company that provides solutions for the detection, identification and assessment of health and bio-threats. The company provides point-of-care (POC) medical testing devices, initially centered on the COVID-19 pandemic, paired with a comprehensive digital health and credentialing platform that offers near real-time tracking of disease. Founded in 2019, Vigilent Labs is headquartered in Charleston, South Carolina, with additional manufacturing and production facilities in Laramie, Wyoming and throughout the United States. For more information, visit www.vigilentlabs.com.
Vikor Scientific and Quantgene announce major advance in precision genomics see more
Starting this March, a South Carolina lab will become ground zero for a preventative test that can detect cancer-causing mutations, risks or tumors in advance through a quick blood sample taken at home or a physician’s office.
S.C. life science organization SCBio and the Charleston Regional Development Alliance linked together Charleston’s Vikor Scientific and California’s Quantgene Inc. when the West Coast company was on the hunt for a lab that could commercialize its AI and genomic-powered preventative care program, Serenity.
Serenity puts to task a deep genomic sequence process that covers 20,000 genes in combination with the disease, medication and lifestyle risks that could contribute to multiple variations of cancer. Along with the blood test, or “liquid biopsy,” it can detect cancerous mutations in the blood, according to Vikor Scientific co-founder Shea Harrelson.
“What this means is that we can detect cancer early enough so that patients don’t have to resort to chemotherapy,” she said during SCBio’s Virtual Meeting Wednesday morning. “They may have options for immunotherapy or aggressive preventative strategies or even excisional therapy.”
Patient-specific health profiles covering personal and family history, as well as lifestyle choices, will brief analysts on how additional risks may contribute to a patient’s likelihood of developing early-stage cancer, thus prompting preventative care.
“With Serenity, we are first-to-market in combining liquid biopsy cancer detection with whole exome sequencing and advanced medical intelligence,” Johannes Bhakdi, founder and CEO of Quantgene, said in a news release. “We hope to unlock a new era in medicine in which trained physicians can detect multiple cancers at early stages in the blood with single molecule precision. Serenity brings genomic technologies to patients within an innovative system of preventative care that we believe will set a new standard in patient-centered personalized medicine. We are excited to take this important step with our partners at Vikor Scientific.”
Vikor Scientific, a hub for medical testing, will process test results in collaboration with Serenity’s proprietary cloud for both individual end-users and health care professionals.
The South Carolina company will launch its public awareness and physician education campaigns alongside the concierge-product release on March 1, according to Scotty Branch, co-founder of Vikor Scientific, and will soon build out its current location in Charleston.
“Our number one goal is to educate physicians throughout the country, which is what we do best,” Branch told GSA Business Report, adding that the team is working to get insurance companies on board with the treatment program now.
“Until then, the liquid biopsy, or the early detection portion, will be on a concierge or cash-paid basis,” he said.
Vikor Scientific will conduct whole exome sequencing and send that information to the Serenity cloud for both physicians and individual consumers, potentially for a variety of uses.
While existing genetic tests on the market like those sold by 23 and Me may be able to offer a surface level detection of certain cancer-causing genetic variations in a patient, Serenity takes genomic testing to the next step of preventative treatment, the company said.
“Genetic mutations only play a role in about 5% to 10% of cancer,” Harrelson said. “So, there’s about 90-95% of cancers that don’t have genetic mutations, and without that, you still have a lot of familial cancers. And most people die from cancer than heart disease or automobile accidents, so this liquid biopsy test will be very important, because if patients have put stress on their body or smoke or other risk factors that can increase their chance for cancer, this liquid biopsy test is pretty painless and a great screening tool for this and other cancers that … like pancreatic cancer. We often don’t find out about pancreatic cancer until stage three or four.”
Taking into account detected at-risk genetic variations, the Vikor-Quantgene team will analyze additional risks for early stages of cancer through the liquid biopsy test, in lieu of more invasive measures, which can detect whether nascent tumors are forming in the body.
“It’s a great continuum of care,” he added. The test analysis could then be used, in tandem with additional data, to launch preventative treatment and care.
“We need to use liquid biopsy as part of an annual or bi-annual screening,” Branch said.
After a Monday Vikor Scientific Board meeting, Branch said 99% of the plans for the facility buildout have been nailed down. The full announcement will come when the company approves the final portion of its development strategy.
“This is an amazing announcement for South Carolina and for economic development, where we are going to build out at our location at 22 West Edge, where Vikor’s location is currently,” he said. The company will start small with 10 to 20 new employees and scale up from there. “That is exciting news that a corporate hub would be located here in Charleston’s West Edge Medical Innovation District."
Executive Partnering, Virtual Exhibit Hall Add Draw for Power of Us Conference Feb. 16-17 see more
With conference registration surging more than 20% past prior record levels and the addition of a “singularly significant innovation announcement focused on cancer treatments and precision medicine advancement”, SCBIO's “The Power of Us” virtual conference Feb. 16-17 is preparing for its largest gathering ever next week... delivered virtually to registrants from across the Palmetto State plus 25 states and 8 countries.
Adding to the excitement is a just-scheduled “major innovation announcement” by a South Carolina company, in tandem with West Coast and German allies, that has significant implications for cancer diagnosis and treatment on a global level, organizers say.
Already in excess of 500 registrants from across America and around the globe, the acclaimed SCBIO conference – the annual gathering of South Carolina’s life sciences community – will also celebrate the rapid growth of the industry and the contributions of its 800+ organizations in helping America and the world overcome the brutal COVID-19 pandemic.
South Carolina life sciences has seen a doubling of firms and 40% increase in life sciences’ direct employment since 2017, which combine to make it the fastest growing industry sector in the state, according to recent data provided by Dr. Joseph Von Nessen, the state's research economist and noted economic development expert with the Moore School of Business at the University of South Carolina.
“Dr. Von Nessen’s data validates that the life sciences industry in South Carolina is experiencing stunning growth, thanks to the combined efforts of our state’s economic development teams, industry partners, research universities, elected officials and other partners,” said SCBIO CEO Sam Konduros. “It’s an exciting time to be a part of an industry that is saving lives and improving quality of care.”
The industry has a $12+ billion economic impact in the Palmetto State, with more than 800 firms located in 42 of 46 counties across the state and over 43,000 professionals employed directly or indirectly in research, development and commercialization of innovative healthcare, medical device, industrial, environmental and agricultural biotechnology products.
Organizers are tight-lipped about the Innovation Announcement details, which will be unveiled at 8:30 a.m. on the second day of the conference—February 17.
“We will say that the implications of the announcement include a new technology that has the ability to detect cancers at the earliest time ever, to further lifespans, and to unlock a new era of precision medicine, ” said Mr. Konduros.
Adding to the draw of the conference are scores of organizations from across America showcasing their capabilities in a virtual exhibit hall, direct 1-to-1 executive meetings on demand via a Partnering Portal, major industry awards and – naturally – top speakers.
Committed presenters include BIO Global CEO Dr. Michelle McMurry-Heath; Microsoft Vice President Jamie Harper, who leads the global team supporting higher education and K-12 initiatives; and Bill Stadtlander, Commercial Leader of Verily, the Google subsidiary focused on life sciences and use of health data and AI to improve lives.
Also speaking at SCBIO 2021 are Courtney Christian, Senior Director of Policy and Research at PhRMA and former leader of the Black Women's Health Imperative; Dr. Harris Pastides, former USC President and outgoing chair of the SC Institute of Medicine and Public Health; Dr. Pat Cawley, CEO of MUSC Health; and Dr. Marjorie Jenkins, Dean of the USC School of Medicine - Upstate and Chief Academic Officer of Prisma Health Upstate, among others.
Themed “The Power of Us,” the 2-day SCBIO 2021 virtual event will feature sessions on The Power of Innovation, The Power of Partnership, and The Power of People – each a fundamental force which drives the state’s surging $12 billion industry that is a key contributor to South Carolina’s expanding knowledge economy.
The conference will also feature SCBIO CEO Sam Konduros delivering the “State of South Carolina’s Life Sciences Industry” address, and release of SCBIO’s 2020 annual report.
Leaders already registered to attend include executives from Presenting Sponsor Vikor Scientific, Champion Sponsor Nephron Pharmaceuticals, Keynote Sponsor Medpoint, Pinnacle Awards Sponsor Softbox and others. Leading biotech and med-tech industry brands participating include BIO, Johnson & Johnson, AVX, PhRMA, AdvaMed, Poly-Med, VWR, Ritedose Corporation, Rhythmlink, ZEUS, Patheon Thermo Fisher, Zverse, Abbott, Alcami, SSOE – Stevens & Wilkinson, and more. All of South Carolina’s research universities – MUSC, Clemson and the University of South Carolina – are represented, as are major healthcare systems, the South Carolina Department of Commerce, SCRA, South Carolina Hospital Association and others.
Registration is open online at the 2021 Virtual Conference section of www.scbio.org. Registration is free to employees of most SCBIO investors and supporters as well as to students interested in life sciences careers, while faculty and teachers can attend the entire conference for $25. General admission tickets are available for as little as $75. Virtual Exhibit space and sponsorships are also available by inquiring at email@example.com.
For additional information on SCBIO or to register for SCBIO 2021, visit www.SCBIO.org.
Vikor Scientific and Quantgene Partner to Launch SerenityTM -- Ground-Breaking Advancement in Precision Genomics, Personalized MedicineFounders take virtual stage at South Carolina life sciences conference to introduce technology see more
Founders take virtual stage at South Carolina life sciences conference to introduce revolutionary ability for early detection of cancer mutations
Santa Monica, CA and Charleston, SC -- Feb. 17, 2021 – Vikor Scientific, a South Carolina-based leading, molecular diagnostics company with a rapidly expanding nationwide footprint, has announced a strategic investment in California-based Quantgene Inc. to accelerate the commercialization of Quantgene’s flagship product, SerenityTM. Serenity provides world-leading accuracy in precision genomics and AI-enabled personalized preventative care.
Quantgene’s Serenity combines advanced next-generation sequencing with proprietary cloud and AI technology to uncover deeper and more meaningful health insights earlier. Serenity will launch with four core components of health protection:
- Liquid biopsy to detect cancer-related mutations in the blood to support early detection
- Deep genomic sequencing across all 20,000 genes for a more complete picture of disease, medication and lifestyle risks
- In-depth patient health profiles including health history, family history and lifestyle to bring more context to test results
- An expert clinical team to provide analysis and connect patients to a network of world-leading medical experts
The combination of these components allow the system to detect, flag and monitor disease and disease risk at earlier stages. Early intervention for potentially fatal conditions like cancer is critical to ensuring better treatment response and long-term outcomes. This is a critical advancement in marrying medicine and technology to ensure the company realizes their mission of extending the average lifespan of members by a decade within a decade.
South Carolina-based Vikor Scientific is a market leader in providing targeted, molecular diagnostics that can improve clinical and economic outcomes. Headquartered in Charleston, S.C., Vikor anchors the WestEdge Life Sciences Campus adjacent to the Medical University of South Carolina and is approaching 400 employees nationwide. The announcement was made at SCBIO 2021, the acclaimed national conference of South Carolina’s life sciences industry which draws industry leaders from around the globe.
In addition to ensuring the successful launch of Serenity commercially, the new partners have plans to launch several downstream liquid biopsy-based clinical oncology products including minimum residual disease detection (“MRD”), recurrence monitoring and companion diagnostics over the next several months. Vikor Scientific will leverage their proven commercialization engine for innovative molecular diagnostics technologies and leverage their growing national salesforce in service of the new product roll outs.
Shea Harrelson, co-founder of Vikor Scientific, said: “In Quantgene, Vikor saw a compelling opportunity to support the commercialization of advanced genomics in the service of preventative care and positively impacting the course of many chronic diseases, starting with cancer. This partnership aligns perfectly with our mission as a company - to improve patient outcomes and prevent unnecessary healthcare costs and delays in treatment by improving diagnostic accuracy, reducing turnaround time and personalizing treatment options.”
Scotty Branch, co-founder of Vikor Scientific added: “Changing the paradigm of healthcare has always been the vision for Vikor Scientific. The platform built by the Quantgene team is revolutionary and certain to accelerate the speed at which we diagnose and treat patients for cancer. Vikor is excited to lead the commercialization and expand on our mission of driving clinical outcomes. And we are particularly excited to do so here in Charleston, where we envision a dynamic future for innovation, growth and expansion of the booming life sciences hub here in South Carolina.”
“With Serenity, we are first-to-market in combining liquid biopsy cancer detection with whole exome sequencing and advanced medical intelligence. We hope to unlock a new era in medicine in which trained physicians can detect multiple cancers at early stages in the blood with single molecule precision.” added Jo Bhakdi, founder and CEO of Quantgene. “Serenity brings genomic technologies to patients within an innovative system of preventative care that we believe will set a new standard in patient-centered personalized medicine. We are excited to take this important step with our partners at Vikor Scientific.”
Alluding to Serenity as a new frontier in science that “promises earlier detection than ever and promises to unlock a new era of medicine,” Branch saluted the role of SCBIO and the Charleston Regional Development Authority in making the announcement a reality.
“I can envision the day when this collaboration leads to a new corporate hub here with new labs and bright new talent from South Carolina medical schools advancing this revolutionary technology,” Branch added. “We credit the efforts of SCBIO and this state in bringing our organization and Quantgene together, and we intend to identify new collaborations and partnerships that advance the future of medicine, and promise a healthier future for our state, country and world.”
Producing and shipping 10,000 Rapid COVID-19 antigen test kits for King of Hammers racing event see more
Vigilent Labs, an advanced health and medical technology company that provides solutions for the detection, identification and assessment of health and bio-threats, has completed and shipped its first major order of Alfa Scientific Instant-View COVID-19 Antigen Test Kits for use in the King of Hammers racing event.
”We have worked diligently for months to progressively and proactively execute the safest off-road racing event possible, and we could not have held this event without the help of Vigilent Labs,” said Dave Cole, Lead for the King of Hammers Race and President of Hammerking Productions. "Our innovative partnership with Vigilent Labs enabled us to navigate public health requirements and deploy a comprehensive digital COVID monitoring solution for pre-screening our racing event attendees to ensure their health and safety."
This project marks an important milestone for Vigilent Labs and the South Carolina life science sector as the company recently announced that it is investing more than $104.6 million and will create over 400 new jobs at its state-of-the-art COVID-19 test manufacturing facility in the Charleston Navy Yard.
"Our Vigilent Labs Medical Systems technology platform is the first digital health credential connecting a real person to a rapid COVID test, taking health surveillance to the Next Level,” said John Falk, President of Vigilent Labs. “With the outstanding support from the entire FedEx organization, we were able to quickly get these important COVID-19 test kits into the hands of the King of Hammers organizers, enabling their public event to go forward in California."
The cost-effective rapid antigen tests, which produce fast and accurate results in seven to 10 minutes, are CE-marked and pursuant to CDC guidance, useful for COVID-19 screening and surveillance. The kits will be immediately put to use by the King of Hammers Racing event, which is being held from January 28 to February 6, 2021, in San Bernardino County, California, to pre-screen attendees for COVID-19. This event is the first widely attended event to deploy the Vigilent Labs’ v.PASS digital credential, the company’s state-of-the-art health monitoring solution, to ensure adherence to increased federal, state and local safety guidelines.
“We take pride in our dependable, fast and efficient transportation mechanisms, which enabled us to help Vigilent Labs to deliver these COVID-19 antigen tests,” said Elizabeth Tonelis, FedEx Sales Executive.
To learn more about Vigilent Labs’ solutions for COVID-19 testing and monitoring, visit www.vigilentlabs.com.
About Vigilent Labs
Vigilent Labs is an advanced health and medical technology company that provides solutions for the detection, identification and assessment of health and bio-threats. The company provides point-of-care (POC) medical testing devices, initially centered on the COVID-19 pandemic, paired with a comprehensive digital health and credentialing platform that offers near real-time tracking of disease. Founded in 2019, Vigilent Labs is headquartered in Charleston, South Carolina, with additional manufacturing and production facilities in Laramie, Wyoming and throughout the United States. For more information, visit https://vigilentlabs.com/.
South Carolina life sciences company adding 148 new jobs to booming industry see more
Vikor Scientific, LLC, a molecular diagnostics company, today announced plans to expand operations in Charleston County. The $1 million investment will create 148 new jobs.
Founded in 2018, Vikor Scientific, LLC specializes in antibiotic stewardship and tangible solutions for the practice of value-based medicine in the treatment of infectious disease. The company provides clinicians with advanced molecular methodology for pathogen detection, quantification and resistance gene identification.
Located at 22 Westedge Street in Charleston, Vikor Scientific, LLC's expansion will increase the company's capacity to assemble and distribute both COVID-19 and full molecular panel testing kits across the country.
The expansion is expected to be completed by January 2021. Individuals interested in joining the Vikor Scientific, LLC team should visit the company's careers webpage.
"The prior backorder of testing supplies was crippling for the U.S. during the beginning of the pandemic, and no one wants to experience that again. This expansion will help us to continue to stay ahead and increase the production of our testing kits for both COVID and our other infectious disease molecular panels by the hundreds of thousands, which is vital as we enter the sick season." -Vikor Scientific Co-Founder Shea Harrelson
"Vikor Scientific, LLC's expansion and the 148 new jobs it will create will have a huge impact in Charleston County and across the state. We couldn't be more excited to continue this partnership and watch them succeed here for years to come." -Gov. Henry McMaster
"Team South Carolina works hard to offer businesses a strong foundation to foster growth and be successful. Vikor Scientific, LLC's decision to expand in Charleston County is an indication that we are doing it right, and we look forward to supporting this great company every step of the way." -Secretary of Commerce Bobby Hitt
"Charleston County offers an environment supportive of innovation, which is a catalyst for our growth in the life sciences industry. We welcome Vikor Scientific's expansion, as it will have a positive impact on our economy with the creation of 148 new jobs." -Charleston County Council Chairman Elliott Summey
"As we continue to respond to the effects of the coronavirus pandemic, the remarkable work of companies like Vikor Scientific has proven critical to keeping our citizens healthy and safe. Not only will this expansion create 148 new jobs in Charleston, but it will increase our ability to provide COVID-19 tests to those who need them throughout the state and across the country. On behalf of the citizens of Charleston, I'd like to thank Vikor Scientific for the lifesaving work they do in our community and wish them Godspeed as they continue to expand operations." -Charleston Mayor John J. Tecklenburg
"Vikor Scientific is a young company making a monumental impact within the life sciences industry, and we are grateful this important work is happening in our backyard. Congratulations to Vikor Scientific on this significant expansion and we look forward to our continued partnership." -Charleston County Economic Development Executive Director Steve Dykes
FIVE FAST FACTS
- Vikor Scientific, LLC is expanding operations in Charleston County.
- The $1 million investment will create 148 new jobs.
- Vikor Scientific, LLC is a molecular diagnostics company.
- Located at 22 Westedge Street in Charleston, S.C.
- Individuals interested in joining the Vikor Scientific, LLC team should visit the company's careers webpage.
MUSC Foundation for Research Development holds Vournakis NAI Induction Ceremony and Adm. Albert Baciocco Innovator of the Year ReceptionMUSC FRD honors innovators, patent recipients at virtual gala... see more
Congratulations to all of the honorees from the recent John N. Vournakis NAI Induction Ceremony and Annual Adm. Albert J. Baciocco Innovator of the Year Reception. Learn about teh honorees and this highly anticipated annual event right here!
Vigilent Labs to call Charleston, South Carolina home see more
Compliments of Charleston Post and Courier
Congratulations to our colleagues in Charleston County for this excellent announcement, advancing the growth of life sciences in South Carolina. Read the full story here.
A technology firm with ties to the U.S. defense industry said Thursday it will invest nearly $105 million in a facility on the former Navy base in North Charleston that the company says will manufacture COVID-19 test kits.
Vigilent Labs said it will hire 400 workers to produce FDA-approved test kits that can detect COVID-19 antibodies and antigens in 10 minutes or less.
Manufacturing will begin in December and the company said it also will move its headquarters to the site at 1105 Truxton Ave. Vigilent is currently based in Alexandria, Va., near the nation’s capital, and it was incorporated in Wyoming. Read on for full details.
Charleston, Vikor Scientific featured in national media see more
Empty hotel rooms, half-full offices, and shuttered retail. The coronavirus has wreaked havoc on the most established commercial real estate asset classes, creating short-term financial crunches and raising long-term secular concerns as remote work is tested and e-commerce rates rise.
Other asset classes, once alternatives, have become institutional investing gold standard. Logistics assets such as warehouses are providing a punch to the portfolio of the world’s largest landlord, Blackstone.
As industrial real estate investing becomes more crowded, and many of the other large asset classes slump, attention is turning to life sciences real estate — or space that’s used by pharmaceutical and biotech companies for research, development, and even manufacturing of new diagnostics, therapies, and vaccines.
The life science industry had been growing rapidly before the pandemic, attracting $17.4 billion in venture capital funding in 2019, up 370% from $3.7 billion in 2008, according to a Cushman & Wakefield report. Funding has continued to pour into the sector, even as coronavirus has slowed down venture funding overall, creating demand for more lab space.
This week's South Carolina life sciences newsletter is hot off the press! see more
Enjoy this week's newsletter from SCBIO featuring updates on South Carolina's inaugural Women in Life Sciences initiatives... a report on MUSC's growing economic impact statewide... details on more Palmetto State organizations stepping up for the greater good... an update from EVP Erin Ford and much, much more... click here to read complete details!
First in nation treatment for MIS-C, COVID-19 complication, at MUSC Shawn Jenkins Children’s HospitalMUSC Shawn Jenkins Children’s Hospital in Charleston on leading edge of treatment see more
When 4-year-old K.J. Griffin arrived at MUSC Shawn Jenkins Children’s Hospital in Charleston, South Carolina, the normally bubbly boy who loves to ride his bike and play outside with his friends was frighteningly limp.
His mother was stunned and exhausted. The little boy she’d worried about for days as his fever spiked had already been to a hospital near their home in rural Smoaks. But the condition K.J. was suffering from was so new and rare that it went unrecognized.
So Talaiyah Stephens watched over her son at home, doing what she could to ease his symptoms but feeling helpless as he got sicker and sicker. “He didn’t want to talk. All he would do was sleep. He’d wake up, throw up, go to the bathroom, then lay back down and go to sleep. He would look at you like he was staring right through you.”
When K.J.’s fever rose to 105 degrees and wouldn’t come down, Stephens came to a decision. She would drive him to MUSC Shawn Jenkins Children’s Hospital, about an hour and 15 minutes away. It was a choice that saved his life.
Dr. David Cole chronicled many MUSC achievements during the 2020 fiscal year see more
CHARLESTON, S.C. (Aug. 14, 2020) – Recently, the Medical University of South Carolina (MUSC) and Medical University Hospital Authority (MUHA) Board of Trustees held their regularly scheduled combined committee sessions and board meeting. With its fiscal year-end closing on June 30, MUSC administrators focused on the multilayered impacts of the novel coronavirus on the operations of all three missions of the institution – education, research and patient care – along with MUSC’s leadership role across the community and state during this pandemic. To support established social distancing guidelines in the COVID-19 era, the MUSC trustees and administrators met via teleconference.
“The ripple effects of the pandemic continue to reach every area of our institution,” said MUSC President David J. Cole, M.D., FACS. “We are committed to battling this virus at every turn and continue to find innovative ways to deliver safe, top-quality education and patient care in the face of this challenge. In addition, we are engaged in ongoing research projects, many which, in collaboration with national networks, are designed to help define how to best treat and mitigate the impact of this virus.”
“Throughout the pandemic, MUSC Health has been recognized and called upon as an essential health care resource, having performed nearly 138,000 diagnostic screening tests, primarily through mobile testing sites in communities across the state,” said Patrick J. Cawley, M.D., CEO of MUSC Health and vice president for Health Affairs, University. “In partnership with the state legislature, MUSC set up mobile screening and collection sites in rural and underserved areas in an intentional bid to reach those who are most vulnerable and too often underserved when it comes to health care. Reliable diagnostic and antibody testing remain key elements of managing this unprecedented statewide health challenge.”
Despite the hurdles posed by COVID-19, Cole chronicled many MUSC achievements during the 2020 fiscal year, including:
- The MUSC Shawn Jenkins Children’s Hospital and Pearl Tourville Women’s Pavilion opened in February.
- MUSC became the only institution in the country to house both a Digestive Disease Research Core Center and a Center for Biomedical Research Excellence in Digestive and Liver Disease.
- MUSC Health West Ashley Medical Pavilion opened as scheduled in December and served 10,418 patients in the first month, with 214 operative procedures.
- The South Carolina Clinical & Translational Research Institute, one of about 60 Clinical and Translational Science Award hubs nationwide, was awarded a $24M five-year renewal.
- Safely held a series of virtual graduation celebrations, including a drive-through diploma pick-up event for its 660 graduates.
- Transitioned more than 3,000 students to online education in response to the novel coronavirus within 24 hours’ notice.
- MUSC was first in the nation to combine drive-through testing with a virtual screening platform for potential COVID-19 patients.
- MUSC and Clemson collaborated to launch the Healthy Me – Healthy SC program to increase health access and fight health disparities statewide. The program began expanding in early 2020 after successful pilots in Anderson, Barnwell and Williamsburg counties.
- MUSC, Clemson and Siemens Healthineers co-hosted a summit in Columbia about artificial intelligence (AI) to bring together faculty, clinicians and engineers. They shared information about current work, new opportunities and discussed the future of AI in health care. The pilot effort funded three joint AI projects with Clemson.
- U.S. News & World Report named MUSC the state’s best hospital for the fifth consecutive year.
- The inaugural 2019 Lowvelo Bike Ride for Cancer Research engaged more than 709 cyclists and 300 volunteers, raising some $650,000 to support MUSC Hollings Cancer Center.
- The U.S. Patent Office granted the MUSC Foundation for Research Development 18 patents.
- MUSC received $25 million from the General Assembly to partner with the South Carolina Department of Health and Environmental Control and the South Carolina Hospital Association to develop and deploy a statewide testing plan. The focus of the plan is on rural and underserved areas of the state. More than 200 testing events/sites have been implemented.
- MUSC Health continues to support the reopening plan and testing strategy for the University of SC, College of Charleston, The Citadel and Clemson University.
The 16-member MUSC/MUHA board voted unanimously to elect James Lemon, DMD, as chairman and Charles W. Schulze, CPA, as vice chairman. Each will serve a two-year term. Lemon is an oral and maxillofacial surgeon by training. A native of Barnwell, he has lived in Columbia for more than three decades. Elected to the MUSC board in 2014, he serves as the medical professional representative from the 2nd Congressional District. Schulze, a Greenwood native, began his first term as an MUSC trustee in 2002 as the lay representative from the 3rd Congressional District. A retired shareholder of a regional accounting and consulting firm, Schulze currently practices and is an expert in financial forensics.
In other business, the board voted to approve:
- The fiscal year 2021 budgets for MUSC (University), the MUSC Health system and MUSC Physicians.
- Moving the spring commencement and graduation date from its originally scheduled date of May 22 to May 15, 2021.
- A seven-year lease to provide new clinical care space for the MUSC Neuro Rehabilitation Institute in Charleston.
- A supplemental HVAC system for the MUSC Hollings Cancer Center Compounding Pharmacy.
- A lease renewal to provide 140 parking spaces at the intersection of Line Street and Hagood Avenue.
The MUSC/MUHA Board of Trustees serves as separate bodies to govern the university and hospital, normally holding two days of committee and board meetings six times a year. For more information about the MUSC Board of Trustees, visit http://academicdepartments.musc.edu/leadership/board/index.html.
About The Medical University of South Carolina
Founded in 1824 in Charleston, MUSC is the oldest medical school in the South as well as the state’s only integrated academic health sciences center with a unique charge to serve the state through education, research and patient care. Each year, MUSC educates and trains more than 3,000 students and nearly 800 residents in six colleges: Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy. The state’s leader in obtaining biomedical research funds, in fiscal year 2019, MUSC set a new high, bringing in more than $284 million. For information on academic programs, visit musc.edu.
As the clinical health system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality patient care available, while training generations of competent, compassionate health care providers to serve the people of South Carolina and beyond. Comprising some 1,600 beds, more than 100 outreach sites, the MUSC College of Medicine, the physicians’ practice plan, and nearly 275 telehealth locations, MUSC Health owns and operates eight hospitals situated in Charleston, Chester, Florence, Lancaster and Marion counties. In 2020, for the sixth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.
MUSC and its affiliates have collective annual budgets of $3.2 billion. The more than 17,000 MUSC team members include world-class faculty, physicians, specialty providers and scientists who deliver groundbreaking education, research, technology and patient care.
U.S. News & World Report releases annual national rankings see more
MUSC Health University Medical Center in Charleston was named by U.S. News & World Report for the sixth year in a row as the No. 1 hospital in South Carolina, with three of the MUSC Health, Charleston Division, specialty areas ranking among the best in the entire country: ear, nose and throat; gynecology; and cancer. Six other MUSC Health programs based in Charleston are considered “high performing” in the 2020-2021 U.S. News & World Report rankings: gastroenterology and GI surgery; nephrology; neurology and neurosurgery; orthopedics; rheumatology and urology. In addition, MUSC Health Florence Medical Center is designated “high performing” in chronic obstructive pulmonary disease (COPD) and heart failure, and MUSC Health Lancaster Medical Center is designated “high performing” in COPD and heart failure.
“These six consecutive years of recognition demonstrate that our teams remain committed to keeping the needs of patients as the focal points of what we deliver every day,” said Patrick J. Cawley, M.D., MUSC Health CEO and vice president for Health Affairs, University. “With all the pressures bearing on the health care industry right now, especially during this pandemic, yet again earning this level of recognition as the leading health care organization in the Charleston area, the Lowcountry and the state engenders a tremendous sense of accomplishment and pride in our teams’ abilities to change what’s possible for those we serve.”
The Best Hospitals 2020-2021 https://health.usnews.com/best-hospitals report is designed to help patients with life-threatening or rare conditions identify hospitals that excel in treating the most difficult cases. The annual report includes consumer-friendly data and information on 4,500 medical centers nationwide in 16 specialties, 10 procedures and conditions. In the 16 specialty areas, 134 hospitals were ranked in at least one specialty. In rankings by state and metro area, U.S. News & World Report recognizes hospitals as high performing across multiple areas of care.
“It is particularly gratifying to see two of the newest hospitals within the MUSC Health system, in our Florence and Lancaster Divisions, recognized in this year’s report,” Cawley said. “Our teams statewide are engaged in delivering health care that is built on quality, safety and innovation at every level.” The Florence and Lancaster hospitals joined the MUSC Health system in March 2019 when MUSC Health acquired four community hospitals.
The U.S. News & World Report Best Hospitals methodologies, in most areas of care, are based largely or entirely on objective measures such as risk-adjusted survival and readmission rates, volume, patient experience, patient safety and quality of nursing, among other care-related indicators.
“For more than 30 years, U.S. News & World Report has been helping patients, along with the help of their physicians, identify the Best Hospitals in an array of specialties, procedures and conditions,” said Ben Harder, managing editor and chief of health analysis at U.S. News. “The hospitals that rise to the top of our rankings and ratings have deep medical expertise, and each has built a track record of delivering good outcomes for patients.”
U.S. News & World Report produces its Best Hospitals rankings with RTI International, a leading research organization based in Research Triangle Park, N.C.
Vikor Scientific featured in Charleston, Columbia and Greenville Business magazines see more
A number of South Carolina-based life sciences companies joined the battle against COVID-19 when the pandemic hit in early March. Prominent among this group is Charleston-based Vikor Scientific, a testing laboratory founded just over two years ago by entrepreneurs Shae Harrelson and Scotty Branch.
Vikor developed a COVID-19 test kit that is now widely used by nursing homes and other healthcare facilities across the nation. The test kit also tests for more than 40 other pathogens known to cause respiratory illness. Click to enjoy the entire article...
ZVerse and Phoenix Specialty Manufacturing step up for South Carolina see more
Two South Carolina companies -- ZVerse and Phoenix Specialty Manufacturing -- jumped into action to meet the needs of the response to the coronavirus, manufacturing vital pieces of equipment at a time when they were urgently needed and unlikely to be easily available for import.
In doing so, they played key roles as the country rushed to provide the medical supplies needed to protect the lives of the sick and their caregivers.
In Columbia, ZVerse began March as a company that helped manufacturers by creating more effective computer files for their production processes. It had the capability to do some 3D printing but did not usually do manufacturing.